Suppr超能文献

2型糖尿病合并肾损伤患者尿肽的发现与验证

Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury.

作者信息

Fu Guangzhen, Du Ye, Chu Lina, Zhang Man

机构信息

Department of Clinical Laboratory, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing 100038, China.

Department of Nephrology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

出版信息

Exp Biol Med (Maywood). 2016 Jun;241(11):1186-94. doi: 10.1177/1535370216629007. Epub 2016 Feb 3.

Abstract

Varying degrees of renal injury could lead to different changes in urinary protein composition. We want to find urinary candidate peptide biomarkers in type 2 diabetic patients with different extents of kidney injury. Two sets of patients were recruited. Discovery set: weak cationic-exchange magnetic beads coupled with matrix-assisted laser desorption ionization time-of-flight mass spectrometry were used to profile the low-molecular weight peptidome in urine samples from type 2 diabetes patients with normoalbuminura and microalbuminuria. The differently expressed urinary peptides were screened by ClinProTools2.1 bioinformatics software and identified through nano-liquid chromatography-tandem mass spectrometry. Verification set: the above screened urinary peptides were validated by use matrix-assisted laser desorption ionization time-of-flight mass spectrometry on another group of type 2 diabetes patients with different extents use of kidney injury. In the screening and identification stages, seven urinary peptides were selected as the most promising biomarker candidates, and they were identified as fragments of vitronectin precursor, isoform 1 of fibrinogen alpha chain precursor, prothrombin precursor and inter-alpha-trypsin inhibitor heavy chain H4. The diagnostic efficacy of these urinary peptides was evaluated by area under the receiver operating characteristic curve, and they were 0.767, 0.768, 0.868, 0.910, 0.860, 0.843, and 0.865, respectively. In the verification stage, m/z 1743.9, 2154, 2175.5, and 2184.9 were decreased as albumin-to-creatinine (Alb/Cre) increased and m/z 2231.1, 2430.8, and 2756.1 were elevated as Alb/Cre rose. These small molecule peptides are related to type 2 diabetes kidney damage, and they may play an important role in monitoring type 2 diabetes.

摘要

不同程度的肾损伤可导致尿蛋白成分发生不同变化。我们想在不同程度肾损伤的2型糖尿病患者中寻找尿候选肽生物标志物。招募了两组患者。发现组:使用弱阳离子交换磁珠结合基质辅助激光解吸电离飞行时间质谱对正常白蛋白尿和微量白蛋白尿的2型糖尿病患者尿液样本中的低分子量肽组进行分析。通过ClinProTools2.1生物信息学软件筛选差异表达的尿肽,并通过纳升液相色谱-串联质谱进行鉴定。验证组:使用基质辅助激光解吸电离飞行时间质谱对另一组不同程度肾损伤的2型糖尿病患者进行上述筛选的尿肽验证。在筛选和鉴定阶段,选择了7种尿肽作为最有前景的生物标志物候选物,它们被鉴定为玻连蛋白前体、纤维蛋白原α链前体同工型1、凝血酶原前体和α-胰蛋白酶抑制剂重链H4的片段。通过受试者操作特征曲线下面积评估这些尿肽的诊断效能,它们分别为0.767、0.768、0.868、0.910、0.860、0.843和0.865。在验证阶段,随着白蛋白与肌酐比值(Alb/Cre)升高,m/z 1743.9、2154、2175.5和2184.9降低,而随着Alb/Cre升高,m/z 2231.1、2430.8和2756.1升高。这些小分子肽与2型糖尿病肾损伤有关,并可能在监测2型糖尿病中发挥重要作用。

相似文献

1
Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury.
Exp Biol Med (Maywood). 2016 Jun;241(11):1186-94. doi: 10.1177/1535370216629007. Epub 2016 Feb 3.
2
Identification of urinary biomarkers for type 2 diabetes using bead-based proteomic approach.
Diabetes Res Clin Pract. 2013 Aug;101(2):187-93. doi: 10.1016/j.diabres.2013.05.004. Epub 2013 Jun 13.
4
Urinary Peptides Associated Closely with Gestational Diabetes Mellitus.
Dis Markers. 2020 Aug 20;2020:8880034. doi: 10.1155/2020/8880034. eCollection 2020.
5
Levels of inter-alpha-trypsin inhibitor heavy chain H4 urinary polypeptide in gestational diabetes mellitus.
Syst Biol Reprod Med. 2021 Dec;67(6):428-437. doi: 10.1080/19396368.2021.1977869. Epub 2021 Oct 4.
8
Two urinary peptides associated closely with type 2 diabetes mellitus.
PLoS One. 2015 Apr 22;10(4):e0122950. doi: 10.1371/journal.pone.0122950. eCollection 2015.
10
The Urinary Peptidome as a Noninvasive Biomarker Development Strategy for Prenatal Screening of Down's Syndrome.
OMICS. 2019 Sep;23(9):439-447. doi: 10.1089/omi.2019.0098. Epub 2019 Aug 5.

引用本文的文献

1
Lysosome-related proteins may have changes in the urinary exosomes of patients with acute gout attack.
Eur J Med Res. 2025 Jan 21;30(1):41. doi: 10.1186/s40001-025-02272-5.
2
Recent progress in mass spectrometry-based urinary proteomics.
Clin Proteomics. 2024 Feb 22;21(1):14. doi: 10.1186/s12014-024-09462-z.
3
4
An Overview of the Posttranslational Modifications and Related Molecular Mechanisms in Diabetic Nephropathy.
Front Cell Dev Biol. 2021 May 28;9:630401. doi: 10.3389/fcell.2021.630401. eCollection 2021.
6
Identification of Urinary CD44 and Prosaposin as Specific Biomarkers of Urinary Tract Infections in Children With Neurogenic Bladders.
Biomark Insights. 2019 Mar 15;14:1177271919835570. doi: 10.1177/1177271919835570. eCollection 2019.
7
Analysis of Urine Composition in Type II Diabetic Mice after Intervention Therapy Using Holothurian Polypeptides.
Front Chem. 2017 Jul 26;5:54. doi: 10.3389/fchem.2017.00054. eCollection 2017.

本文引用的文献

1
Two urinary peptides associated closely with type 2 diabetes mellitus.
PLoS One. 2015 Apr 22;10(4):e0122950. doi: 10.1371/journal.pone.0122950. eCollection 2015.
2
Identification of urinary biomarkers for type 2 diabetes using bead-based proteomic approach.
Diabetes Res Clin Pract. 2013 Aug;101(2):187-93. doi: 10.1016/j.diabres.2013.05.004. Epub 2013 Jun 13.
3
Oxidant stress and skeletal muscle microvasculopathy in the metabolic syndrome.
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):150-9. doi: 10.1016/j.vph.2012.07.002. Epub 2012 Jul 11.
4
Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited.
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):139-49. doi: 10.1016/j.vph.2012.03.005. Epub 2012 Mar 27.
5
Oxidative stress and diabetic complications.
Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
6
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
Am J Nephrol. 2010;31(5):469-70. doi: 10.1159/000292500. Epub 2010 Apr 22.
7
Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
Am J Nephrol. 2010;31(5):462-5; discussion 466-7. doi: 10.1159/000313553. Epub 2010 Apr 22.
8
Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
Am J Nephrol. 2010;31(5):458-61; discussion 468. doi: 10.1159/000292501. Epub 2010 Apr 22.
9
Urine in clinical proteomics.
Mol Cell Proteomics. 2008 Oct;7(10):1850-62. doi: 10.1074/mcp.R800001-MCP200. Epub 2008 Jul 30.
10
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.
J Am Soc Nephrol. 2007 Apr;18(4):1353-61. doi: 10.1681/ASN.2006080872. Epub 2007 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验